HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Metaxalone

HCID 178909114
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
1189944-95-3
Standard SMILES
Cc1cc(C)cc(OCC2CNC(=O)O2)c1
InChIKey
IMWZZHHPURKASS-UHFFFAOYSA-N
Molecular formula
C12H15NO3
Average molar mass
221.25 g/mol

Overview

Metaxalone is an aromatic ether.

Names & identifiers

Preferred name
Metaxalone
IUPAC
5-[(3,5-dimethylphenoxy)methyl]-1,3-oxazolidin-2-one
English name
Metaxalone D6
Molecular formula
C12H15NO3
Molecular weight
221.26

Names & synonyms

METAXALONE1665-48-1SkelaxinZoraneMethaxalonumMetaxalonMethoxoloneAHR-4382-Oxazolidinone, 5-[(3,5-dimethylphenoxy)methyl]-5-[(3,5-Dimethylphenoxy)methyl]-1,3-oxazolidin-2-oneMetaxalonaMetassalone
Show more names
[2H6]-Metaxalone5-[(3,5-dimethyl-d6-phenoxy)methyl]oxazolidin-2-one5-[[3,5-bis(trideuteriomethyl)phenoxy]methyl]-1,3-oxazolidin-2-oneMetaxalone D6Q: What is Metaxalone D6 Q: What is the CAS Number of Metaxalone D6 Q: What is the storage condition of Metaxalone D6 Q: What are the applications of Metaxalone D6
MetaxalonumFlexura5-(3,5-Xyloloxymethyl)oxazolidin-2-oneCL 39,148DTXSID30232695-[(3,5-Xylyloxy)methyl]-2-oxazolidinone2-Oxazolidinone, 5-((3,5-xylyloxy)methyl)-5-((3,5-Dimethylphenoxy)methyl)-2-oxazolidinone

Database identifiers

CAS
1189944-95-3
ChEMBL
CHEMBL1079604
ChEBI
CHEBI:6797
UNII
1NMA9J598Y
EC Number
216-777-6
Nikkaji
J7.549C

Properties

Computed structural propertiesFilling in

XLogP
2.2
Topological polar surface area
47.6 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
3
Rotatable bonds
3
Heavy atoms
16
Formal charge
0
Complexity
247

Experimental & physicochemical properties

Chemical ClassesPharmaceutical
DrugsPharmaceuticals
LogP2.3
OdorOdorless
Color/Form · 2 items

White to almost white crystalline powder

Crystals from ethyl acetate

Solubility · 3 items

Freely soluble in chloroform; soluble in methanol and 95% ethanol; practically insoluble in ether

Practically insoluble in water

1.28e+00 g/L

Human Drugs · 3 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Boiling PointBP: 223 °C at 1.5 mm Hg
Melting Point · 2 items

122 °C

122 °C

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 46 reports by companies from 2 notifications to the ECHA C&L Inventory.

Hazard information

FDA Requirements · 1 item

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, including metaxalone, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Safety & protection

Storage ConditionsMetaxalone tablets should be stored at a controlled room temperature of 15 - 30 °C.
Disposal Methods · 2 items

SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

SRP: At the time of review, regulatory criteria for small quantity disposal are subject to significant revision, however, household quantities of waste pharmaceuticals may be managed as follows: Mix with wet cat litter or coffee grounds, double bag in plastic, discard in trash.

Chemistry & industry

Pharmacology

Pharmacodynamics · 1 item

Metaxalone is a skeletal muscle relaxant indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.

Mechanism of Action · 3 items

The mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system depression.

Metaxalone is a CNS depressant that has sedative and skeletal muscle relaxant effects. The precise mechanism of action of the drug is not known. The skeletal muscle relaxant effects of orally administered metaxalone are minimal and are probably related to its sedative effect. The drug does not directly relax skeletal muscle and, unlike neuromuscular blocking agents, does not depress neuronal conduction, neuromuscular transmission, or muscle excitability.

The mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system depression. Metaxalone has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

Biological Half-Life · 2 items

9.2 (+/- 4.8) hours

Terminal half-life /is/ 9.0 + or - 4.8 hours

Metabolism/Metabolites · 4 items

Probably hepatic.

Biotransformations...studied in dogs and in man. 5-(3-methyl-5-carboxyphenoxymethyl)-2-oxazolidinone, major metabolite, is excreted in urine and feces; this also occurs in urine as ester glucuronide. Fission of ether linkage...affords...3,5-xylenol and 5-hydroxymethyloxazolidinone. Oxazolidinone ring is stable in mammals.

Yields 5-(5-carboxy-3-methylphenoxymethyl)-2-oxazolidone in man & in dogs, yields 3,5-dimethylphenol in man and in dogs. /From table/

Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.

FDA Pharmacological Classification · 6 items

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Physical Description
Solid
Collision Cross Section · 2 items

152.3 Ų [M+Na]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID3023269]

152.15 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

storage temp.
-20 °C · -20°C
solubility
Acetonitrile: Soluble
form
A solid
Symbol(GHS)
7 · GHS07
Signal word
Warning

Toxicology

InteractionsAdditive CNS depression may occur when metaxalone is administered concomitantly with other CNS depressants, including alcohol. If metaxalone is used concomitantly with other depressant drugs, caution should be used to avoid overdosage.
Hepatotoxicity · 1 item

According to the product brochure, metaxalone may cause jaundice, although there are no specific case reports of hepatotoxicity from metaxalone in the literature and no prospective trials with routine monitoring of aminotransferase levels. Given its long history, metaxalone appears to be without significant hepatotoxicity.

Environmental Fate · 3 items

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 530(SRC), determined from a structure estimation method(2), indicates that metaxalone is expected to have low mobility in soil(SRC). Volatilization of metaxalone from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 2.7X10-10 atm-cu m/mole(SRC), using a fragment constant estimation method(3). Metaxalone is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 4.4X10-6 mm Hg at 25 °C(SRC), determined from a fragment constant method(4). Biodegradation data were not available(SRC, 2010).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 530(SRC), determined from a structure estimation method(2), indicates that metaxalone is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 2.7X10-10 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). According to a classification scheme(5), an estimated BCF of 24(SRC), from an estimated log Kow of 2.6(6) and a regression-derived equation(7), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data were not available(SRC, 2010).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), metaxalone, which has an estimated vapor pressure of 4.4X10-6 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase metaxalone is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 2.2 hours(SRC), calculated from its rate constant of 1.7X10-10 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Particulate-phase metaxalone may be removed from the air by wet or dry deposition(SRC). Metaxalone does not contain chromophores that absorb at wavelengths >290 nm(4), and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).

Milk ConcentrationsEXPERIMENTAL: It is not known whether metaxalone is distributed into milk.
Effluent Concentrations · 1 item

Metaxalone was detected in one of three wastewater treatment plant effluents associated with facilities involved in the manufacture of pharmaceuticals in New York; 35-38 samples were collected from each plant between 2004 and 2009. The concentration of metaxalone was 3,800 ug/L in the one New York sample, which receives 20% of its discharge from a pharmaceutical formulation facility. The median concentration ranged from 0.5 to >400 ug/L. It was not detected in twenty-three plants across the US were analyzed once between 2004 and 2009 as part of a National Survey; more than half of these plants receive hospital discharge. Detection limit = 0.011 ug/L. These findings suggest that current manufacturing practices at pharmaceutical formulation facilities can result in pharmaceuticals concentrations from 10 to 1000 times higher than those typically found in wastewater treatment plant effluents(1).

Soil Adsorption/Mobility · 1 item

Using a structure estimation method based on molecular connectivity indices(1), the Koc of metaxalone can be estimated to be 530(SRC). According to a classification scheme(2), this estimated Koc value suggests that metaxalone is expected to have low mobility in soil.

Human Toxicity Excerpts · 5 items

/CASE REPORTS/ A 29-year old female with a history of depression was found dead in a hotel room. The death scene investigation found empty pill bottles and an empty liter bottle of wine. Metaxalone, a centrally acting muscle relaxant, along with citalopram, ethanol, and chlorpheniramine were identified in the postmortem samples and quantitated by gas chromatography-mass spectrometry. The concentration of metaxalone in femoral vein blood was 39 mg/L. The heart blood concentration was 54 mg/L. Femoral vein blood concentrations of citalopram and chlorpheniramine were 0.77 mg/L and 0.04 mg/L, respectively. Ethanol levels were 0.13 g/dL in vitreous and 0.08 g/dL in heart blood. Other tissue samples were also analyzed. The authors consider the metaxalone concentrations toxic and potentially fatal. The citalopram concentrations were lower than those reported in fatal cases for this drug alone. Death was ascribed to polydrug abuse/overdose with metaxalone a major contributor. This represents the first reported case to our knowledge in which a metaxalone overdose significantly contributed to death.

/CASE REPORTS/ A case is presented of a 54-year-old white female found dead in a secured apartment. Postmortem toxicologic analysis of the heart blood identified acetaminophen (97 mg/L), citalopram (0.4 mg/L), gabapentin (24 mg/L) and metaxalone (21 mg/L). The metaxalone concentration is within the range of previously reported fatalities involving metaxalone. The medical examiner ruled that the cause of death was metaxalone and gabapentin intoxication and the manner of death was suicide.

/SURVEILLANCE/ The purpose of this study was to describe the pattern of metaxalone ingestions by young children reported to poison control centers. METHODS: Cases were all metaxalone ingestions by patients aged 0 to 5 years reported to Texas poison control centers during 2000 to 2007. Cases with multiple substance ingestions and lack of follow-up were excluded. Cases were analyzed for selected demographic and clinical factors. Of 148 total cases, 56.8% were boys. The distributions by management site were 56.1% on-site, 22.3% already at/en route to a health care facility, and 21.6% referred to a health care facility. Final medical outcomes were no effect for 90.5% cases, minor effect for 8.1%, moderate effect for 0.7%, and major effect for 0.7%. Specific clinical effects reported were drowsiness (11), vomiting (3), agitation (2), rash (1%), tachycardia (1), and ataxia (1). Pediatric metaxalone ingestions reported to Texas poison control centers usually resulted in minor or no effect. Most ingestions did not require hospitalization.

/SURVEILLANCE/ Few data exist on potentially adverse metaxalone ingestions in adults. All metaxalone ingestions involving patients aged > or = 20 years during 2000-2006 were retrieved from Texas poison control centers. Exclusion criteria were lack of follow-up or multiple substance ingestion. Cases were analyzed for selected demographic and clinical factors. Of the 142 patients, 66.2% were female. Dose ingested was reported for 61 patients. Of those cases with a reported dose, distribution by management site was 29.5% on-site, 59.0% already at/en route to health care facility, and 11.5% referred to health care facility. Final medical outcome was 'no effect' for 50.8% cases, 'minor effect' for 31.1%, and 'moderate effect' for 18.0%. The more common adverse clinical effects reported were drowsiness (27.9%), tachycardia (6.6%), agitation (6.6%), nausea (4.9%), dizziness (4.9%), slurred speech (4.9%), and tremor (4.9%). A moderate medical outcome occurred in 13.6% of ingestions of <or=2400 mg and 20.5% of ingestions of >2400 mg. Management involved a health care facility in 18.2% of ingestions of <or=2400 mg and 100.0% of ingestions of >2400 mg. This study found that adult ingestions of higher doses of metaxalone, particularly >2400 mg, were associated with more serious medical outcomes and were managed at health care facilities.

Artificial Pollution SourcesMetaxalone's production and use as a medication(1) may result in its release to the environment through various waste streams(SRC).
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Metaxalone

vLess-DILI-concern

5

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Environmental Bioconcentration · 1 item

An estimated BCF of 24 was calculated in fish for metaxalone(SRC), using an estimated log Kow of 2.60(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).

Volatilization from Water/Soil · 1 item

The Henry's Law constant for metaxalone is estimated as 2.7X10-10 atm-cu m/mole(SRC) using a fragment constant estimation method(1). This Henry's Law constant indicates that metaxalone is expected to be essentially nonvolatile from water surfaces(2). Metaxalone's Henry's Law constant indicates that volatilization from moist soil surfaces may not occur(SRC). Metaxalone is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 4.4X10-6 mm Hg(SRC), determined from a fragment constant method(3).

Non-Human Toxicity Excerpts · 2 items

/LABORATORY ANIMALS: Acute Exposure/ In dogs, no LD50 could be determined as the higher doses produced an emetic action in 15 to 30 minutes.

/LABORATORY ANIMALS: Acute Exposure/ When determining the LD50 in rats and mice, progressive sedation, hypnosis and finally respiratory failure were noted as the dosage increased.

Regulatory information

FDA Requirements · 1 item

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, including metaxalone, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Safety data

Signal word
Warning
Symbol(GHS)
GHS07

1NMA9J598Y

METAXALONE

Physiologic Effects [PE] - Centrally-mediated Muscle Relaxation

Established Pharmacologic Class [EPC] - Muscle Relaxant

Metaxalone is a Muscle Relaxant. The physiologic effect of metaxalone is by means of Centrally-mediated Muscle Relaxation.

METAXALONE

MeSH Pharmacological Classification · 1 item

Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.

Absorption, Distribution and Excretion · 6 items

The absolute bioavailability of metaxalone from Skelaxin tablets is not known.

Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.

800 L

68 +/- 50 L/h [Subjects received 1×400mg tablet under fasted conditions]

Although plasma protein binding and absolute bioavailability of metaxalone are not known, the apparent volume of distribution (V/F ~ 800 L) and lipophilicity (log P = 2.42) of metaxalone suggest that the drug is extensively distributed in the tissues. Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.

Peak plasma concentrations of metaxalone occur approximately 3 hours after a 400 mg oral dose under fasted conditions. Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 + or - 4.8 hours. Doubling the dose of skelaxin from 400 mg to 800 mg results in a roughly proportional increase in metaxalone exposure as indicated by peak plasma concentrations (Cmax) and area under the curve (AUC). Dose proportionality at doses above 800 mg has not been studied. The absolute bioavailability of metaxalone is not known

Cellular LocationsMembrane

Uses & manufacturing

Uses · 2 items

MEDICATION

Use (kg) in USA (2002): 115000

Methods of Manufacturing · 2 items

LUNSFORD ET AL, J AM CHEM SOC 82, 1166 (1960); LUNSFORD, US PAT 3,062,827 (1962 TO AH ROBINS).

Prepared by heating urea and 3-(3',5'-dimethylphenoxy)-1,2-propanediol to 200 °C

Formulations/PreparationsOral: Tablets: 800 mg Skelaxin (scored) (King).
Use ClassificationPharmaceuticals

Applications

UsesIt is a muscle relaxant used to relax muscles and relieve pain.

Uses(Metaxalone D6) Labeled Metaxalone, intended for use as an internal standard for the quantification of Metaxalone by GC- or LC-mass spectrometry.

For more Human Toxicity Excerpts (Complete) data for METAXALONE (6 total), please visit the HSDB record page.